Merck to Acquire Afferent Pharmaceuticals

Dateline City: KENILWORTH, N.J. & SAN MATEO, Calif. KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Michael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orAfferentMedia:Susan Kinkead, 415-509-3610orInvestors:Dulce Dizon, 650-286-1276 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Afferent MSD Source Type: news